Adam Mayerson, MD
Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1457451015
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Corcept Therapeutics at 50.2% of the total. 2025 is the largest year on record at $2,580, 2.1 times the $1,227 reported in 2019.
Across 150 payments — averaging $32.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$2K
- Amgen$319
- Insulet Corporation$225
- Novo Nordisk$209
- AstraZeneca$196
- Ipsen Biopharmaceuticals, Inc$147
- plus $1K from 24 others
Across 95 payments — averaging $1591.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$151K
What the payments were for
- Speaking & faculty fees$2,29348%
- Food & beverage$2,32248%
- Education$2044%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 2 | $2,417 |
| Amgen(2 entities) | 30 | $319 |
| Insulet Corporation | 10 | $225 |
| Novo Nordisk | 23 | $209 |
| AstraZeneca(2 entities) | 11 | $196 |
| Ipsen Biopharmaceuticals, Inc | 9 | $147 |
| Abbott | 6 | $130 |
| Dexcom, Inc. | 4 | $129 |
| Medtronic(2 entities) | 7 | $119 |
| Zealand Pharma US, Inc. | 3 | $111 |
| Amarin Pharma, Inc. | 7 | $108 |
| Eisai Inc. | 3 | $75 |
| Lilly USA, LLC | 3 | $68 |
| Merck | 4 | $66 |
| Ultragenyx Pharmaceutical Inc. | 2 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Shire North American Group Inc | 2 | $41 |
| Companion Medical, Inc. | 2 | $35 |
| Ascensia Diabetes Care US Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Radius Health, Inc. | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Pfizer | 2 | $28 |
| Aytu Biopharma, Inc. | 2 | $28 |
| Senseonics, Incorporated | 1 | $24 |
| Acerus Pharmaceuticals Corporation | 1 | $21 |
| Valeritas, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| BD | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$2,417
How this compares
$4,818 in reported general payments places this provider in the 70th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 411 | $719,650 |
| JardianceEmpagliflozin | 373 | $492,214 |
| TrulicityDulaglutide | 172 | $316,543 |
| MounjaroTirzepatide | 185 | $305,923 |
| Tresiba Flextouch U-200Insulin Degludec | 98 | $173,567 |
| TradjentaLinagliptin | 94 | $104,759 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $98,221 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 51 | $78,057 |
| Tresiba Flextouch U-100Insulin Degludec | 108 | $78,007 |
| JanuviaSitagliptin Phosphate | 62 | $73,834 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $66,627 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 38 | $62,261 |
| RybelsusSemaglutide | 31 | $55,299 |
| Humalog Kwikpen U-100Insulin Lispro | 125 | $44,016 |
| FarxigaDapagliflozin Propanediol | 32 | $41,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $209 | $792,310483 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $33 | $659,234505 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $68 | $638,414402 claims |
| MerckJanuvia, Janumet Xr, Janumet | $66 | $114,81489 claims |
| AstraZenecaFarxiga | $196 | $41,74632 claims |
| Johnson & JohnsonInvokana | $17 | $32,19724 claims |
| Sanofi-aventis U.S. LLCLantus | $65 | $4,30915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in New Haven
- Ania JastreboffNew Haven$536K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Gerald ShulmanNew Haven$194K
- Karl InsognaNew Haven$68K
- Clemens BergwitzNew Haven$31K
- Richard KibbeyNew Haven$18K
- Peter TebbenNew Haven$17K
- Surani FernandoNew Haven$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.